Skip to main content

Pharma News

Get the latest news from world and India’s leading pharmaceutical companies Pharma Industry, pharmaceutical marketing, generic drugs, and Complete news for Pharmacy and Life Sciences professionals.

  • Meditation eases anxiety, fatigue and pain for women undergoing breast cancer biopsies, new research says.Researchers from the Duke Cancer Institute in Durham, US found that during such period even music is effective, but only to a lesser extent.

  • Using body mass index (BMI) to gauge health is a wrong practice as it is a deeply flawed measure, reveals a study while adding that BMI should not be the primary goal for maintaining good health.

  • Children with childhood attention deficit hyperactivity disorder (ADHD) the most commonly diagnosed mental disorder of children are at a high risk of developing obesity, a new study has found.

    [adsense:336x280:8701650588]

  • Abbott and Alere Inc announced a definitive agreement for Abbott to acquire Alere, significantly advancing Abbott's global diagnostics presence and leadership. Under the terms of the agreement, Abbott will pay $56 per common share at a total expected equity value of $5.8 billion. Once the transaction is completed, Abbott will become the leading diagnostics provider of point of care testing. Abbott's total diagnostics sales will exceed $7 billion after the close.

  • Mersana Therapeutics and Takeda Pharmaceutical Company Limited  announced that they have entered a new strategic partnership granting Takeda rights to Mersana’s lead product candidate, XMT-1522, outside the United States and Canada. The deal also expands an existing collaboration between the companies to provide Takeda with additional access to Mersana’s Fleximer® antibody-drug conjugate (ADC) platform and grants Mersana an option at the end of Phase 1 to co-develop and co-commercialize one of these programs in the United States. In addition, the companies will co-develop new payloads for use with ADCs.

    XMT-1522 is an investigational, Fleximer-based ADC therapy that targets HER2-expressing tumors, including breast, gastric and non-small cell lung cancers. Preclinical data suggest that XMT-1522 may have anti-tumor activity in patients with HER2 low-expressing cancers as well as in patients with HER2 high-expressing cancers that do not respond to currently available HER2-targeting therapies. Mersana anticipates filing an Investigational New Drug application (IND) for XMT-1522 with the U.S. Food and Drug Administration (FDA) in mid-2016.

Subscribe to Pharma News